Is genetic testing for opioid addiction ready for prime time? Two companies are selling tests to physicians and workers comp programs -- but academic geneticists say they're getting ahead of the science. Read the MedPage Today story here.
Sen. Edward Markey (D.-Mass.) has called on the Justice Department, the FDA, and the FTC to look into Purdue Pharma's claims that OxyContin lasts 12 hours. (Los Angeles Times)
Alzheimer's may result from the brain's attempts to fight off infection, new research suggests. (The New York Times)
The FDA delayed making a decision on Sarepta's Duchenne muscular dystrophy drug eteplirsen. (FierceBiotech)
A researcher suggests play can help children with autism hone their thinking skills. (Spectrum)
An Italian patient's compulsion to speak French after a brain injury caused by a vascular anomaly. (NeuroSkeptic)
Mouse study suggests opioids may actually prolong chronic pain. (Science)
Probuphine, an implantable formulation of buprenorphine, won FDA approval to treat patients who are addicted to opioids, but are already on stable low doses of buprenorphine.
NeuroBreak: Genetic Tests for Opioid Addiction; Alzheimer's Infection
Aucun commentaire:
Enregistrer un commentaire